Home › Trials › NCT06297551
Clinical trial Recruiting at 1 site Observational Ages 18 and up

Tracking leukemia stem cells in blood for acute myeloid leukemia treatment

Official title: Prospective Study of Leukemia Stem Cells Fractional Change in Peripheral Blood and Its Correlation With Therapeutic Outcome in Acute Myeloid Leukemia

Run by Stony Brook University · NCT06297551 · Data updated 2026-11-12

This study is testing if checking for certain leukemia markers in the blood can help doctors predict how well treatment will work for people with acute myeloid leukemia.

More Acute Myeloid Leukemia trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorStony Brook University
Academic / other
Locations1 site (Stony Brook, New York)
StatusRecruiting
StartedMay 17, 2024
Main results expectedMay 31, 2027
Study endsJune 30, 2027
Registry record updatedAugust 20, 2026
Trial IDNCT06297551 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults diagnosed with acute myeloid leukemia who are eligible for treatment at the research center.

Probably not a fit

Patients who do not have elevated levels of CLL1A and CD45RA positive cells at the time of diagnosis may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the potential of using leukemia stem cell markers, specifically CLL1 and CD45RA, found in peripheral blood as a non-invasive method to predict treatment outcomes in patients with acute myeloid leukemia (AML). Traditionally, treatment decisions are based on invasive bone marrow biopsies performed at the end of each treatment cycle. By monitoring these markers early in the treatment cycle, the study seeks to provide timely insights that could guide therapeutic regimen selection and improve patient care. The study will quantify the presence of these markers using flow cytometry to assess their correlation with treatment efficacy.

Why it matters

Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for patients with acute myeloid leukemia.

How similar studies have gone: While the use of biomarkers in leukemia treatment is an evolving field, this specific approach of tracking leukemia stem cells in peripheral blood is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* diagnosis of acute myeloid leukemia
* ability to receive treatment for acute myeloid leukemia at the research center
* elevated values of CLL1A and CD45RA positive cells at the time of diagnosis

Where it's running

  • Stony Brook Cancer Center
    Stony Brook, New York, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Acute Myeloid Leukemia 453Stony Brook University 32
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.